Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLGW) EBIT (2016 - 2017)

Bone Biologics (BBLGW) has disclosed EBIT for 2 consecutive years, with -$1.3 million as the latest value for Q4 2017.

  • Quarterly EBIT rose 57.92% to -$1.3 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2017, up 87.13% year-over-year, with the annual reading at -$3.2 million for FY2025, 23.33% up from the prior year.
  • EBIT for Q4 2017 was -$1.3 million at Bone Biologics, down from -$1.1 million in the prior quarter.
  • The five-year high for EBIT was $2.0 million in Q2 2017, with the low at -$9.1 million in Q1 2016.